In vitro assay development and HTS of small molecule human ABAD/17β-HSD10 inhibitors as therapeutics in Alzheimer’s Disease
MetadataShow full item record
A major hallmark of Alzheimer’s disease (AD) is the formation of neurotoxic aggregates composed of the amyloid-β peptide (Aβ). Aβ has been recognized to interact with numerous proteins, resulting in pathological changes to the metabolism of patients with AD. One such mitochondrial metabolic enzyme is amyloid-binding alcohol dehydrogenase (ABAD), where altered enzyme function caused by the Aβ-ABAD interaction is known to cause mitochondrial distress and cytotoxic effects, providing a feasible therapeutic target for AD drug development. Here we have established a high-throughput screening platform for the identification of modulators to the ABAD enzyme. A pilot screen with a total of 6759 compounds from the NIH Clinical Collections (NCC) and SelleckChem libraries and a selection of compounds from the BioAscent diversity collection have allowed validation and robustness to be optimized. The pilot screen revealed 16 potential inhibitors in the low µM range against ABAD with favorable physicochemical properties for blood-brain barrier penetration.
Aitken , L , Baillie , G , Pannifer , A , Morrison , A , Jones , P S , Smith , T K , McElroy , S P & Gunn-Moore , F J 2017 , ' In vitro assay development and HTS of small molecule human ABAD/17β-HSD10 inhibitors as therapeutics in Alzheimer’s Disease ' SLAS Discovery , vol 22 , no. 6 , pp. 676-685 . DOI: 10.1177/247255521769796
© 2017 Society for Laboratory Automation and Screening. This work has been made available online in accordance with the publisher’s policies. This is the author created, accepted version manuscript following peer review and may differ slightly from the final published version. The final published version of this work is available at: https://doi.org/10.1177/247255521769796
DescriptionThis research was funded by the Scottish Universities Life Science Alliance (SULSA) assay development fund. This research was also kindly supported by The Rosetrees Trust and The Alzheimer’s Society, specifically The Barcopel Foundation, and partly funded by the MSD Scottish Life Sciences fund. As part of an ongoing contribution to Scottish life sciences, MSD Limited, a global health care leader, has given substantial monetary funding to the Scottish Funding Council for distribution via SULSA to develop and deliver a high-quality drug discovery research and training program.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.